Posted by Michael Wonder on 22 Apr 2024
Kura Oncology receives breakthrough therapy designation for ziftomenib in NPM1 mutant AML
22 April 2024 - Ziftomenib is the first investigational treatment to be granted breakthrough therapy designation for NPM1 mutant AML.
Kura Oncology today announced that its investigational drug, ziftomenib, has been granted breakthrough therapy designation by the US FDA for the treatment of patients with relapsed/refractory NPM1 mutant acute myeloid leukaemia.
